Abstract: In contrast, 21 specimens were sensitive to zidovudine-TP, of which 12 had WT genotypes, four had T215Y/F, and five had T69S-insertions along with T215Y/F mutations.
Abstract: This assay exploits the different biochemical mechanisms for zidovudine-resistance conferred by either Q151 M or T215Y/F mutations and the inability of conventional RT assays to detect T215Y/F-associated zidovudine resistance.
Abstract: We show that enzymatic resistance to zidovudine-TP is specific to MNR RT and is distinguishable from both wild-type (WT) and RT containing classical zidovudine-resistant mutations (D67N,
Persistence of earlier HIV-1 drug resistance mutations at new treatment failure.
Abstract: After changing from zidovudine- to stavudine-containing regimens, the thymidine analogue mutations (especially M41L and T215Y/F) were found at new treatment failure in almost all patients.
Development of drug resistance in HIV-1 patients receiving a combination of stavudine, lamivudine and efavirenz.
PMID: 12385703
2002
International journal of antimicrobial agents
Abstract: Results showed that viruses carrying primary mutations, usually K103N, T215Y and M41L, presented higher levels of HIV-1 RNA, suggesting an association between a precise mutation pattern and treatment failure.
Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine.
Abstract: Four of these seven patients also had thymidine analogue-associated mutations (TAM) (T215Y/F [2/4], M41L [1/4], D67N [2/4] and K70R [1/4]).
Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy.
PMID: 11170234
2001
Journal of clinical laboratory analysis
Abstract: The most frequent RT mutations were T215Y/F, M41L, and M184V (41.9, 40.8, and 40.8%, respectively), while L63P, L10R/V, and A71V/T (58, 41.9, and 34.4%, respectively) were the most represented protease substitutions.
Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid.
PMID: 11242181
2001
Journal of acquired immune deficiency syndromes (1999)
Abstract: A median infectious dose (IC50) increase of fourfold for any drug was found in 7 patients, and in 2 was > tenfold for zidovudine (genotype M41L + T215Y) and lamivudine (genotype M184V), respectively.
Abstract: Zidovudine-resistance mutations M41L and/or T215Y were the commonest, found in 20% (6 of 30 participants).
4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.
PMID: 11302824
2001
Antimicrobial agents and chemotherapy
Abstract: These 4'-E analogs also suppressed replication of various drug-resistant HIV-1 clones, including HIV-1(M41L/T215Y), HIV-1(K65R), HIV-1(L74V), HIV-1(M41L/T69S-S-G/T215Y), and HIV-1(A62V/V75I/F77L/F116Y/Q151M).
Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant.
PMID: 11343221
2001
The Journal of infectious diseases
Abstract: The infant had proviral DNA with evidence of RT mutations (M41L, L74V, and T215Y) and 3 PR substitutions (K20R, M36I, and V82A).
Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors.
PMID: 11353634
2001
Antimicrobial agents and chemotherapy
Abstract: Resistance to AZT, d4T, and ABC could be found in the absence of the T215Y/F mutations.
Prevalence of the T215Y mutation in human immunodeficiency virus type 1-infected pregnant women in a New York cohort, 1995--1999.
Abstract: From 1997 through 1999, the prevalence of the zidovudine resistance mutation T215Y was 9.7% among pregnant women, and the human immunodeficiency virus type 1 (HIV-1) load in those with resistant virus was higher than that measured in women with wild-type HIV-1.
HIV mutation literature information.
PMID: 
2002
Antiviral therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT